<DOC>
	<DOC>NCT00110929</DOC>
	<brief_summary>The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).</brief_summary>
	<brief_title>Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Completed one of the qualifying studies (i.e., patient previously took part in an Amgen study investigating the drug AMG 073 and its effects on secondary hyperparathyroidism [HPT]; in particular parathyroid hormone [PTH], calcium and phosphorus levels in blood associated with kidney failure) Must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study Pregnant or nursing females Experienced a myocardial infarction within 3 months before day 1 Have an unstable medical condition, defined as having been hospitalized, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Sensipar®</keyword>
	<keyword>Secondary HPT</keyword>
	<keyword>Mimpara®</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>calcimimetic</keyword>
	<keyword>End-Stage Renal Disease (ESRD)</keyword>
</DOC>